Furthermore, our results also indicate that ICG was an unsatisfactory method to select patients with malignant IPMN, prompting us to challenge the molecular analysis of TGF-β/SMAD4 signaling in IPMN (25). The gene discussed is TGFB1; the disease is pancreatic intraductal papillary-mucinous neoplasm.